Literature DB >> 17061222

Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis.

M Cakir1, Z Kapran, D Basar, C A Utine, F Eroglu, I Perente.   

Abstract

PURPOSE: Parafoveal telangiectasis (PT) is a developmental or acquired microvascular abnormality of the macula. Leakage of the abnormal parafoveal capillaries leads to macular edema with subsequent decrease in visual acuity. Intravitreal triamcinolone acetonide is recently widely used in the management of intraocular proliferative, edematous, and neovascular diseases.
METHODS: This report presents the evaluation of three cases with PT in whom intravitreal triamcinolone acetonide (IVTA) injection was performed. Fundus fluorescein angiography (FA) and optical coherence tomography (OCT) were used in follow-up of the patients.
RESULTS: Following pars plana intravitreal injection of 4 mg of triamcinolone acetonide, the patients had angiographic improvement of the macular edema and minimal decrease in retinal thickness on OCT, accompanied by improvement in visual acuity and subjective visual assessment.
CONCLUSIONS: The results of the present study on parafoveal capillary telangiectasis suggest that the intravitreal injection of triamcinolone acetonide may be a therapeutic option to increase visual acuity and decrease vascular leakage on FA. Following IVTA procedure, follow-up of these patients with both OCT and FA is important for correct clinical evaluation. Future studies on this method seem to be warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17061222     DOI: 10.1177/112067210601600508

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  8 in total

1.  Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Authors:  Buğra Karasu; Betul Onal Gunay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-25       Impact factor: 3.117

2.  Intravitreal bevacizumab therapy for idiopathic macular telangiectasia.

Authors:  Yoko Matsumoto; Mitsuko Yuzawa
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

3.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 4.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

5.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

6.  Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex).

Authors:  Mohamed Loutfi; Thomas Papathomas; Ahmed Kamal
Journal:  Case Rep Ophthalmol Med       Date:  2014-06-17

7.  CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS.

Authors:  Rie Osaka; Chieko Shiragami; Aoi Ono; Mamoru Kobayashi; Yukari Takasago; Ayana Yamashita; Akitaka Tsujikawa
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

8.  Multimodal Imaging Findings and Treatment with Dexamethasone Implant in Three Cases of Idiopathic Macular Telangiectasia Type 1.

Authors:  Paola Cirafici; Maria Musolino; Michela Saccheggiani; Carlo Enrico Traverso; Massimo Nicolò
Journal:  Case Rep Ophthalmol       Date:  2021-04-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.